Mirati Therapeutics: JOCO publishes results from KRYSTAL-1 study of adagrasib

Mirati Therapeutics announced the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRAS inhibitor, demonstrating durable IC activity in patients living with KRAS-mutated NSCLC with untreated CNS metastases. This result is clinically meaningful as CNS metastases are present in 27%-42% of patients living with KRASG-mutated NSCLC at diagnosis and are linked to worse prognosis and higher rates of disease progression in the CNS. Read the publication, here. Data with adagrasib from KRYSTAL-1 demonstrating the first prospective evaluation of a KRAS inhibitor in untreated CNS metastases were based on 25 enrolled patients (19 radiographically evaluable per CNS RECIST v1.1) who had received a median of 1 prior systemic therapy. Results showed an IC objective response rate of 42% and IC disease control rate of 90%. High concordance between IC and systemic activity was observed. The median IC progression-free survival was 5.4 months and median overall survival 11.4 months. Notably, findings demonstrate a manageable safety profile consistent with previous reports of adagrasib with few CNS-specific adverse events. The publication of this data follows the recent inclusion of adagrasib in the NCCN guidelines for CNS Cancers.